New Trial for Potential Lupus of the Skin Treatment
Thursday, January 5, 2012
Rigel Pharmaceuticals, Inc. began a new Phase 1 clinical trial
looking at a potential treatment for discoid lupus (lupus of the skin). Applied to the skin, R333 may be useful in treating acute and chronic phases of this potentially disfiguring disorder. R333 is a JAK/SYK inhibitor, which means it may inhibit Januse Kinase (JAK) and Spleen Tyrosine Kinase(Syk), both of which play a part in regulating inflammation. For more information, check Rigel Pharmaceutical's website at http://www.rigel.com/
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms